Liposomal Glutathione
What is Glutathione?
Glutathione (GSH) is a small intracellular antioxidant made from three amino acids: glutamate, cysteine and glycine. It is synthesised inside cells through two ATP-dependent steps and exists mainly in a reduced form, GSH, which can be oxidised to glutathione disulfide (GSSG). The balance between these forms is commonly used as an indicator of cellular redox state (Forman et al., 2009).
Its role extends beyond simply neutralising reactive species. Glutathione helps protect protein thiols, participates in peroxide metabolism, and acts as a cofactor or substrate for multiple antioxidant and detoxification enzymes. It is therefore closely integrated into the systems cells use to manage oxidative stress and maintain redox homeostasis (Forman et al., 2009).
Glutathione is also present within mitochondria, where it helps protect membranes and other cellular structures from reactive oxygen species generated during normal respiration. Because mitochondrial redox balance is closely linked to energy production and cellular resilience, this mitochondrial pool is particularly relevant to ageing biology (Ribas et al., 2014).
The body produces glutathione endogenously rather than depending on a single dietary source. Its availability is influenced by precursor amino acids, synthesis, recycling and utilisation. This is why both direct glutathione supplementation and precursor strategies such as Glycine + NAC (GlyNAC) have been studied as different ways of influencing glutathione status.
Liposomal glutathione is glutathione incorporated into phospholipid-based vesicles. The purpose of this delivery format is to change how orally administered glutathione is presented to, and handled by, the gastrointestinal system. Human pilot studies suggest that liposomal formulations can raise measured glutathione levels, although the direct clinical literature remains relatively small (Sinha et al., 2018; Solnier et al., 2026).
For broader context on oxidative stress, mitochondrial function and other cellular pathways involved in healthy ageing, see Longevita’s Science of Ageing and ingredient research library.
Below, we review what is known about oral glutathione delivery, the direct evidence for liposomal glutathione, and the wider research linking glutathione biology to healthy ageing.
Oral Glutathione, Formulation and Bioavailability
Research on oral glutathione has produced different results depending on formulation, dose and study duration. In an earlier randomised, double-blind, placebo-controlled study, 500 mg of standard oral glutathione taken twice daily for four weeks did not significantly alter erythrocyte glutathione, redox status or the oxidative-stress biomarkers measured in that trial (Allen & Bradley, 2011).
Longer-term research has not been uniformly negative. In a six-month randomised trial involving 54 healthy adults, standard oral glutathione at 250 or 1,000 mg/day increased glutathione stores in blood, erythrocytes, plasma and lymphocytes, with larger changes generally observed at the higher dose (Richie et al., 2015). These findings show why oral glutathione cannot be treated as a single intervention independent of dose, duration and formulation.
Liposomal delivery has been investigated as another strategy. In a one-month pilot trial, healthy adults taking 500 or 1,000 mg/day of liposomal glutathione showed increases in glutathione measured in whole blood, erythrocytes, plasma and peripheral blood mononuclear cells (Sinha et al., 2018).
A 2026 randomised crossover pilot study compared standard, liposomal and micellar glutathione in 14 healthy volunteers. The pharmacokinetic data indicated that formulation influenced whole-blood glutathione exposure. Mean responses were higher with the liposomal formulation than with standard glutathione, although the strongest statistically significant pairwise comparisons in that study involved the micellar versus standard formulations (Solnier et al., 2026).
Taken together, these studies support formulation as an important variable in oral glutathione research, while also showing that the evidence base for liposomal glutathione is still much smaller than the broader literature on glutathione biology.
Systemic Healthy-Ageing Effects of Glutathione
1. Glutathione Levels and Redox Balance
The most direct human evidence for liposomal glutathione concerns glutathione status itself. In the one-month Sinha pilot study, whole-blood glutathione increased by approximately 40%, erythrocyte glutathione by 25%, plasma glutathione by 28%, and peripheral blood mononuclear-cell glutathione by 100% at measured study time points (Sinha et al., 2018).
Those changes were accompanied by a roughly 35% reduction in plasma 8-isoprostane and a 20% reduction in the oxidised-to-reduced glutathione ratio. These are biomarker-level findings rather than proof of a disease-treatment effect, but they demonstrate that liposomal glutathione was capable of altering measured redox biology in the study participants (Sinha et al., 2018).
Because glutathione participates directly in peroxide metabolism and maintenance of cellular redox state, this is one of the clearest mechanistic links between glutathione availability and protection from oxidative stress (Forman et al., 2009).
2. Mitochondrial Protection and Oxidative Stress
Mitochondria continually generate reactive species during respiration and therefore depend on effective antioxidant systems. Mitochondrial glutathione helps limit lipid peroxidation and oxidative injury within this energy-producing compartment (Ribas et al., 2014).
This relationship is relevant to healthy ageing because oxidative stress and mitochondrial dysfunction often occur together. However, the strongest human evidence connecting improved glutathione status with broader mitochondrial outcomes currently comes from GlyNAC trials rather than from liposomal glutathione itself.
In a 16-week randomised trial in older adults, GlyNAC supplementation corrected glutathione deficiency and was associated with improvements in oxidative stress and mitochondrial fuel oxidation, alongside changes in several other age-related measures (Kumar et al., 2023). This supports the biological importance of glutathione availability, but the result should not be interpreted as direct evidence that liposomal glutathione produces the same outcomes.
For another Longevita ingredient focused on mitochondrial energy production and oxidative protection, see the research on Coenzyme Q10.
3. Immune-Cell Activity
Glutathione helps maintain the intracellular redox environment required for normal immune-cell function. In the Sinha liposomal glutathione pilot study, supplementation was associated with increases in natural-killer-cell cytotoxicity and lymphocyte proliferation (Sinha et al., 2018).
The reported changes were substantial in the measured parameters, including a 400% increase in natural-killer-cell cytotoxicity and a 60% increase in lymphocyte proliferation. Because this was a small pilot study in healthy adults, these findings are best interpreted as evidence of altered immune-cell activity rather than as proof that liposomal glutathione prevents or treats infection or immune disease (Sinha et al., 2018).
4. Glutathione-Dependent Detoxification and Cellular Protection
Glutathione participates in the metabolism of reactive electrophiles and other compounds through glutathione-dependent enzymes, including glutathione S-transferases. It also contributes to the removal of peroxides and the protection of cellular proteins and membranes from oxidative damage (Forman et al., 2009).
These biochemical functions are especially relevant in tissues such as the liver, where glutathione-dependent conjugation contributes to the processing of endogenous and exogenous compounds. In this context, “detoxification” refers to defined biochemical conjugation and antioxidant pathways rather than a general cleansing effect.
5. Glutathione and Ageing Biology: What the GlyNAC Evidence Shows
Ageing has been associated with greater oxidative stress and changes in glutathione metabolism. Human precursor studies provide evidence that lower availability of glycine and cysteine can constrain glutathione synthesis in older adults, providing one biological explanation for reduced glutathione status with age.
A 24-week GlyNAC pilot study in older adults reported improvements in glutathione deficiency, oxidative stress, mitochondrial dysfunction, inflammation, insulin resistance, endothelial dysfunction, genotoxicity, muscle strength and cognition (Kumar et al., 2021).
The subsequent 16-week randomised GlyNAC trial similarly reported improvements across glutathione status, oxidative stress, mitochondrial function, inflammatory and metabolic measures, endothelial function and physical performance (Kumar et al., 2023).
These studies strengthen the case that glutathione availability is relevant to several processes associated with ageing. They do not, however, establish that liposomal glutathione itself reproduces every GlyNAC finding. Direct liposomal trials and precursor trials should therefore be read as complementary but distinct evidence.
Glutathione and Skin Ageing / Pigmentation Evidence
Glutathione has also been studied in relation to skin pigmentation and selected measures of skin ageing. This work has primarily used standard oral reduced or oxidised glutathione rather than liposomal formulations, so it provides evidence about glutathione biology rather than direct formulation-specific proof.
In a 12-week randomised study in healthy women, 250 mg/day of reduced glutathione or oxidised glutathione was associated with lower melanin indices than placebo at some anatomical sites. The reduced-glutathione group also showed improvements in selected measures of wrinkles and skin elasticity (Weschawalit et al., 2017).
A systematic review of the clinical literature concluded that oral glutathione may influence skin lightening or pigmentation measures, but results were inconsistent and often limited to specific anatomical sites or relatively small studies (Sitohang & Ninditya, 2020).
Accordingly, the skin evidence is suggestive rather than definitive. It supports continued research into glutathione and melanogenesis, oxidative stress and skin appearance, but it should not be interpreted as a guaranteed cosmetic outcome for any individual or as direct evidence for a particular liposomal product.
Clinical Evidence, Dose and Safety
The direct clinical evidence for liposomal glutathione remains limited. The principal human study involved 12 healthy individuals taking 500 or 1,000 mg/day for one month. Both doses increased glutathione measured in several blood and cellular compartments, reduced selected oxidative-stress markers and were associated with changes in immune-cell activity (Sinha et al., 2018).
The 2026 crossover pilot study of 14 healthy adults adds evidence that oral glutathione exposure differs by formulation. It compared standard, liposomal and micellar glutathione and found formulation-dependent differences in whole-blood exposure, while the statistically strongest pairwise findings were for micellar versus standard glutathione (Solnier et al., 2026).
Standard oral glutathione has a broader clinical literature. A six-month randomised trial using 250 or 1,000 mg/day increased glutathione stores in healthy adults (Richie et al., 2015), while an earlier four-week trial using 500 mg twice daily did not detect significant changes in the redox or oxidative-stress measures it assessed (Allen & Bradley, 2011). The difference between these studies reinforces the importance of study duration, dose, population and formulation.
Short- to medium-term human studies have generally reported good tolerability. The one-month liposomal pilot study reported no severe adverse events (Sinha et al., 2018). Longer-term safety data are available for standard oral glutathione over six months, but should not automatically be treated as equivalent evidence for liposomal formulations (Richie et al., 2015).
The timing of observed changes depends on the outcome being measured. In the liposomal pilot study, blood glutathione changes were detectable within the study period and some of the largest increases were seen by approximately two weeks. Skin outcomes in oral glutathione research have typically been assessed over about 12 weeks, while broader healthy-ageing outcomes in GlyNAC research have been evaluated over 16 weeks or longer (Sinha et al., 2018; Weschawalit et al., 2017; Kumar et al., 2023). These are study durations, not guaranteed timelines for an individual response.
Pregnant or breastfeeding individuals, people taking prescription medicines, and anyone managing a diagnosed medical condition should discuss supplementation with a healthcare professional. This is particularly important when glutathione supplementation is being considered alongside medical treatment, because glutathione participates in redox and drug-metabolism pathways.
Overall, current human evidence supports glutathione as an important regulator of cellular redox balance and shows that oral supplementation can influence glutathione status. Liposomal delivery has promising direct human data, but the evidence base is still relatively small; claims about broader healthy-ageing outcomes should remain clearly distinguished from findings generated with standard oral glutathione or GlyNAC precursor supplementation.